← Leaderboards
James L Abbruzzese
Duke University
$10,558,825
Attributed
$14,698,321
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,924,839 · 8
By mechanism
U54$8,226,518 · 1
UM1$6,068,118 · 1
P20$5,424,221 · 1
U01$1,690,741 · 2
P30$1,327,072 · 2
R21$188,169 · 1
Top collaborators
- Elizabeth C Dees6 shared
- Andrea Wang-Gillam6 shared
- Christopher M Counter1 shared
Most similar at Duke University
Same institution · by research overlap
- Michael Barry Kastan$65,974,699
- David Reardon$8,732,934
- John H Sampson$43,413,436
- Nelson J. Chao$27,968,804
- Jeffrey None Crawford$10,066,024
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical TrialsNeoplasm /Cancer ChemotherapyResearch PersonnelCooperative StudyAngiogenesisProtocols DocumentationDesignCancer PatientNovel TherapeuticsMalignant NeoplasmsEnrollmentProgramsCommunitiesOperationTumorBaseAntineoplasticsAnticancer ResearchCombination Cancer TherapyPharmacokineticsDrug Screening /EvaluationDosageNeoplasm /Cancer Pharmacology
Grant awards (32)
Clinical Protocol and Data Management$300,386
P30 · FY2024 · CA · contact PI
Clinical Protocol and Data Management$295,137
P30 · FY2023 · CA · contact PI
Clinical Protocol and Data Management$294,847
P30 · FY2022 · CA · contact PI
Adapting K-MDS to detect KRAS-mutant ctDNA$188,169
R21 · FY2022 · CA
Clinical Protocol and Data Management$295,053
P30 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$141,649
P30 · FY2020 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$1,702,907
UM1 · FY2019 · CA · contact PI
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)$715,167
UM1 · FY2019 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$1,703,461
UM1 · FY2018 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$170,500
UM1 · FY2018 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$891,969
UM1 · FY2016 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$884,114
UM1 · FY2016 · CA · contact PI
SPORE in Pancreatic Cancer$521,256
P20 · FY2009 · CA · contact PI
SPORE in Pancreatic Cancer$1,042,511
P20 · FY2007 · CA · contact PI
SPORE in Pancreatic Cancer$1,119,167
P20 · FY2006 · CA · contact PI
Targeted Assessment of Antiangiogenic Therapy$291,510
U54 · FY2006 · CA · contact PI
Targeted Assessment of Antiangiogenic Therapy$1,416,862
U54 · FY2005 · CA
SPORE in Pancreatic Cancer$941,287
P20 · FY2005 · CA
Targeted Assessment of Antiangiogenic Therapy$1,573,040
U54 · FY2004 · CA
SPORE in Pancreatic Cancer$900,000
P20 · FY2004 · CA
Targeted Assessment of Antiangiogenic Therapy$1,978,308
U54 · FY2003 · CA
SPORE in Pancreatic Cancer$900,000
P20 · FY2003 · CA
Targeted Assessment of Antiangiogenic Therapy$1,948,703
U54 · FY2002 · CA
CORRELATED CLINICAL-LABORATORY PHASE I TRIALS$425,968
U01 · FY2002 · CA
CORRELATED CLINICAL-LABORATORY PHASE I TRIALS$41,165
U01 · FY2002 · CA
Targeted Assessment of Antiangiogenic Therapy$903,095
U54 · FY2001 · CA
CORRELATED CLINICAL-LABORATORY PHASE I TRIALS$274,839
U01 · FY2001 · CA
Targeted Assessment of Antiangiogenic Therapy$115,000
U54 · FY2001 · CA
CORRELATED CLINICAL-LABORATORY PHASE I TRIALS$40,097
U01 · FY2001 · CA
CORRELATED CLINICAL-LABORATORY PHASE I TRIALS$10,260
U01 · FY2001 · CA
PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS$496,374
U01 · FY2000 · CA
CORRELATED CLINICAL-LABORATORY PHASE I TRIALS$402,038
U01 · FY2000 · CA